Santhera Pharmaceuticals Achieves Significant Financing Milestone
Santhera Pharmaceuticals has recently finalized a remarkable USD 13 million royalty monetization agreement aimed at accelerating the global launch of their innovative treatment, AGAMREE® (vamorolone). This significant announcement showcases the company's ongoing commitment to expanding its reach in addressing rare neuromuscular diseases.
A Partnership with R-Bridge and Partners Group
The agreement, initially set in September, involves a strategic collaboration with R-Bridge, an affiliate of the CBC Group. It allows Santhera to benefit from 25% of net royalties earned on AGAMREE® from Catalyst Pharmaceuticals, Inc. in North America and Sperogenix Therapeutics Ltd in China. A notable addition to this financing initiative is Partners Group, who has contributed a substantial portion of the funding. Their involvement underscores the confidence major financial institutions have in Santhera’s vision and AGAMREE's potential.
Understanding the Royalty Monetization Structure
In this deal, the payments to both Partners Group and R-Bridge are capped at an agreed amount, providing Santhera with a safeguard. Once this ceiling is reached, the North American and Chinese royalties will revert back to Santhera, enhancing their revenue stream in the long run. Furthermore, Santhera retains vital buy-back rights over the royalty flow, ensuring control over future earnings from AGAMREE, following an earlier agreement with R-Bridge that entitled them to 75% of net royalties from the same sources.
CEO's Perspective on Strategic Growth
Dario Eklund, the Chief Executive Officer of Santhera Pharmaceuticals, expressed enthusiasm about the closure of this agreement, remarking on its significance for supporting the company's strategy and the global rollout of AGAMREE. His comments reflect the value this financing brings to enhancing the company's capabilities in the rare disease sector.
About AGAMREE and Santhera Pharmaceuticals
AGAMREE® (vamorolone) has been developed as a dissociative steroid, a novel treatment modality geared towards addressing Duchenne muscular dystrophy (DMD). The unique therapeutic profile of AGAMREE distinguishes it from standard corticosteroids, providing a valuable alternative for patients with high unmet medical needs. Santhera holds exclusive worldwide licensing rights for all indications concerning AGAMREE through a partnership with ReveraGen.
Regulatory Approvals and Market Access
This groundbreaking treatment has already gained various vital approvals across multiple jurisdictions, including the U.S. Food and Drug Administration (FDA), the European Commission (EC), and Health Canada, along with several other regulatory bodies in key international markets. This position places Santhera and AGAMREE in a favorable stance to meet the growing demand for effective therapies in neuromuscular disorders.
Collaboration with Catalyst Pharmaceuticals and Sperogenix Therapeutics
In North America, AGAMREE is sublicensed to Catalyst Pharmaceuticals, while Sperogenix Therapeutics handles distribution in China and parts of Southeast Asia. These partnerships expand Santhera's market presence and support its aspirations to improve patient outcomes globally.
Connecting with Santhera
For more insights and information, stakeholders are encouraged to connect directly with Santhera Pharmaceuticals. The company remains committed to transparency and engaging with investors, partners, and the medical community regarding its innovative solutions.
Contact Information
Catherine Isted, Chief Financial Officer
Contact: IR@santhera.com
Frequently Asked Questions
What is the purpose of the royalty monetization agreement?
The agreement helps finance the global launches of AGAMREE®, allowing Santhera to further invest in its development and commercialization strategies.
Who are Santhera's partners in this agreement?
Santhera collaborated with R-Bridge and Partners Group to secure the financing needed for the royalty monetization agreement.
What is AGAMREE®?
AGAMREE® (vamorolone) is a treatment designed for patients with Duchenne muscular dystrophy, providing a novel alternative to traditional corticosteroids.
How does the royalty structure work?
The royalty payments are capped, ensuring that after a certain threshold, revenues revert to Santhera, which also holds buy-back rights on the royalty stream.
What regulatory approvals has AGAMREE® received?
AGAMREE® has received approvals from the FDA, EC, and Health Canada, among others, enabling it to be commercialized in key global markets.
